Navigation Links
Study Suggests Soy Protein May Reduce Prostate Cancer Risk
Date:10/4/2007

ique combination of functional, nutritional and economic benefits to our customers.

Headquartered in St. Louis, Missouri, USA, with annual revenue exceeding $1 billion, the company was formed through an alliance between Bunge Limited (NYSE: BG) and DuPont (NYSE: DD). For more information, visit http://www.solae.com.


'/>"/>
SOURCE Solae
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 2Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 3Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 4Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 5Health News:Webcast Alert: MicroRNA: The Year in Review 2Health News:PrimeDoc Renews and Expands Three-Year Contract with Ingenious Med 2Health News:PrimeDoc Renews and Expands Three-Year Contract with Ingenious Med 3Health News:NCCN Guidelines for Non-Small Cell Lung Cancer Updated to Incorporate Maintenance Therapy 2Health News:NCCN Guidelines for Non-Small Cell Lung Cancer Updated to Incorporate Maintenance Therapy 3Health News:Caffeine Doesn't Sober You Up 2Health News:Caffeine Doesn't Sober You Up 3